Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
PwC
Fierce Pharma
PwC projects continued growth for rest of 2026, fueled by M&A
With pharma and life sciences deals surpassing $65 billion in Q1, analysts from PwC have declared the “biopharma ecosystem is back to full health.”
Kevin Dunleavy
Jun 17, 2026 5:00am
Pharma's 'urgent need for reinvention': PwC's call to action
Jan 8, 2026 6:00am
Pharma and life sci M&A volume dropped 8% in 2024: PwC
Dec 12, 2024 5:00am
Biopharma dealmaking still rising, but M&A value steady: PwC
Jun 20, 2024 8:27am
Biotech IPO window will ‘gradually reopen’ in 2024: PwC
Dec 14, 2023 9:39am
M&A values halve, volumes plunge. Will we ever see deals again?
Dec 8, 2022 8:25am
